Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
|発行||Occams Business Research & Consulting Pvt. Ltd.||商品コード||348577|
|出版日||ページ情報||英文 140 Pages
|CRISPRの世界市場の考察・機会分析・市場シェア・将来予測 Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022|
|出版日: 2016年04月29日||ページ情報: 英文 140 Pages||
Clustered regularly-interspaced short palindromic repeats also known as CRISPR is a gene editing tool. CRIPSR commercialization began in 2012 with emergence of number of startups and venture capitalists and showing their interest in infusing money into this technology. Academic and research firms are the main consumers of CRISPR gene editing tool followed by biotechnology companies. The number of patents for CRISPR is outclassing the patents of other gene editing tools such as ZFN and TALEN. The market is driven by high demand for plasmids, synthetic genes and high quality gene slicing techniques. Growing drug discovery, biotechnology and proteomics markets are also driving the market growth.
The market is This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate.
The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Some of the major companies include Editas, Intellia, Sigma Eldrich, Oregene, Gene Script, Thermo Fisher Scientific and others. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific.